Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.54 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28215302 | 0.94 | EPHX1 (0.65) | EPHX1EPHX2 | |
| SCHEMBL9390 | 0.87 | EPHX1 (0.95) | EPHX1EPHX2CASP2SMN1; SMN2 | |
| SCHEMBL7747419 | 0.85 | EPHX1 (0.56) | EPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL25229277 | 0.84 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25277850 | 0.84 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25275041 | 0.84 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25271304 | 0.84 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25270721 | 0.84 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25276783 | 0.84 | EPHX1 (1.00) | EPHX1EPHX2CASP2 | |
| SCHEMBL25228459 | 0.84 | EPHX1 (1.00) | EPHX1EPHX2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0622361-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6194396-B1 | ANTIALLERGENS; ANTIINFLAMMATION AGENTS; AUTOIMMUNE DISEASE; ANTISHOCK AGENTS; ANALGESICS; E.G., A 4 OR 7-PHENYLALKYLENE-OXYBENZIMIDAZOLE UNSUBSTITUTED OR SUBSTITUTED IN THE 1,2,3-POSITION WITH AN OXY, AMINO AND/OR THIO GROUP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| US-6169095-B1 | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| US-6083961-A | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| US-5922711-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| EP-0596406-B1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |